Enter your email address
to be notified when new
courses become available.
|
This activity is provided by the
Network for Continuing
Medical Education.

This activity is supported by an educational grant from the
sanofi-aventis Group.

|
|
INTRODUCTION AND PROGRAM DESCRIPTION
eMedicine is delighted to offer this free CME activity based on a round-table discussion videotaped in Philadelphia, Pennsylvania, on April 7, 2006. The Network for Continuing Medical Education (NCME) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. NCME designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™.
Please note that the course is accredited only for physicians (MD, DO, or equivalent). All other participants receive a certificate of completion.
Many individuals have 1 or more cardiovascular or metabolic risk factors, including dyslipidemia, insulin resistance, hypertension, and intra-abdominal adiposity, and are at risk for cardiovascular disease and for metabolic disorders such as diabetes. Recent evidence suggests that a newly described physiologic system, the endocannabinoid system, is involved in lipid and glucose metabolism and that overactivity of this system is associated with risk factor development. Blockade of cannabinoid-1 (CB1) receptors, however, has been shown to modify several of these risk factors.

|
The discussion features Sidney C. Smith, Jr, MD, FACP (chair), Louis J. Aronne, MD, FACP, and Daniel J. Rader, MD. These noted thought leaders address the following topics:
- Diabetes and Obesity in the United States
- Cardiometabolic Risk Factors
- Patient Identification and Current Treatment Options
- The Endocannabinoid System and Future Treatment Options
|
|

To learn more about cardiometabolic risk factors, take the new course Cardiovascular Risk Reduction: Focus on Managing Cardiometabolic Risk. |
|